SignalEU/UK

Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis

First BTK inhibitor FDA filing acceptance in both relapsing and primary progressive MS.

What changed

First BTK inhibitor FDA filing acceptance in both relapsing and primary progressive MS.

Why it matters

First BTK inhibitor FDA filing acceptance in both relapsing and primary progressive MS. — impact context not separately stored; see What changed.

Sources